The patient has been on an antidepressant for eight months. Still fatigued. Still not sleeping. Still sitting across from you with the same flat look she had at her first visit. Normal panel, two dose adjustments, no meaningful change.
Nobody checked her hormones.
That’s not a criticism of her previous provider. It’s how the training works. Depression routes to psychiatry. Hormones route somewhere else. The two systems rarely talk to each other, and the patient lands in the gap.
The connection between hormones and depression is more direct than the standard psychiatric workup acknowledges. The monoamine hypothesis, the theory that depression is caused by low serotonin, has never been confirmed. A 2022 umbrella review by Moncrieff et al. in Molecular Psychiatry examined the full body of evidence and found no consistent evidence of a direct link between serotonin levels and depression. Meanwhile, testosterone, progesterone, and estradiol each have measurable, documented mechanisms of action on mood. Deficiency in any of them can present identically to major depressive disorder.
Hormone levels are measurable. Serotonin deficiency is not. That’s where the workup should start.
[Podcast Embed Placeholder: Spotify/Apple or YouTube embed for Episode 96]
Why is depression treated as a serotonin problem?
The dominant model for treating depression since the late 1980s has been the monoamine hypothesis. The simplified version: depression is caused by low serotonin, and medications that increase serotonin availability should correct it.
That hypothesis was an educated guess that became clinical standard. It happened without the kind of objective confirmation medicine requires for almost every other condition. The first SSRIs arrived, the model was adopted broadly, and a generation of providers trained inside a system that presented it as settled science.
The Moncrieff 2022 umbrella review is the most thorough examination of that hypothesis to date. Across multiple study designs, the review found no consistent evidence linking serotonin levels to depression. Some included studies showed elevated serotonin associated with depressive symptoms. That’s the inverse of what the entire treatment class was built on.
This doesn’t mean SSRIs produce no benefit in any patient. Some do respond. But if the mechanism they were designed to target hasn’t been confirmed as the actual cause of the condition, the benefit is likely arriving through a different pathway. That matters clinically because it means SSRIs aren’t addressing a root cause. They’re managing a presentation.
And the problem goes further than the serotonin question. The six most widely prescribed SSRIs have been shown in vitro to potently disrupt steroidogenesis, decreasing androgens and altering the estrogen-to-androgen ratio at concentrations close to clinical therapeutic levels. They interfere with the same hormonal system a thorough depression workup should be evaluating first. Weight gain, metabolic disturbance, blunted motivation, decreased libido: these are among the most reported side effects of long-term SSRI use, and they’re consistent with reduced mitochondrial function. Not random. They reflect what happens when cellular energy production is impaired.
The point is not that prescribing an SSRI represents a failure in clinical judgment. It doesn’t. It’s that the model most providers were handed never taught them to look upstream before reaching for that tool.
What is depression if it is not a disease?
Depression is a symptom. That reframe is not semantic. It changes the entire clinical approach.
A disease has a known cause, a discrete pathology, a predictable treatment. Strep throat has a culturable pathogen and a near-certain resolution within days. Type 1 diabetes has measurable biomarkers and confirmable tissue pathology. Depression has none of that. No lab test confirms it. No imaging finding. No biopsy. The diagnosis is built from symptom checklists.
A symptom is a signal. It points upstream. Depression can be driven by nutritional deficiency, lack of sunlight, chronic sleep disruption, hormonal deficiency, or some combination. When the dominant model treats it as a disease with a single known driver, the workup becomes a symptom count rather than an investigation. The patient describes low mood, fatigue, and brain fog. The provider reaches for an SSRI. Nobody checks hormones. Nobody asks about cycle regularity, or whether testosterone has ever been measured, or what a full thyroid panel actually shows.
There’s also a metabolic layer most workups miss entirely. Serotonin is not a passive neurotransmitter. It’s a stress-adaptive signal. When it’s chronically elevated, or pharmacologically prolonged by an SSRI, it suppresses oxidative metabolism and shifts cellular function toward glycolysis. That’s the less efficient, more inflammatory pathway. The weight gain, metabolic changes, and blunted motivation that accompany long-term SSRI use are consistent with that shift. Not incidental. What happens downstream when that trade-off is sustained.
Treating a hormonal deficiency with a drug that further suppresses metabolic function is not a neutral clinical decision. It’s movement in the wrong direction.
How does testosterone affect depression?
Consider a man in his 40s. Former collegiate athlete. Strong career, intact family, no obvious psychosocial explanation for how he feels. He’s been symptomatic for about a year. Low mood, irritability, cognitive fog, no motivation, a sense that he’s watching his own life from a distance.
His provider runs standard labs. Everything comes back within range. He gets a diagnosis of major depressive disorder and a prescription for an SSRI. The SSRI blunts his remaining libido, contributes to erectile dysfunction, leaves him emotionally flat without resolving anything underneath. He now needs additional medications for the side effects of the first one.
Nobody checked his testosterone.
Low testosterone has been independently associated with clinical depression in multiple peer-reviewed studies and meta-analyses. The mechanism is not complicated once you see it. Testosterone is dopaminergic. It drives motivation, effort-reward processing, and the internal sense of agency that makes a person recognize themselves. When it’s deficient, the clinical picture can look identical to major depressive disorder: low mood, irritability, loss of drive, cognitive fog, hopelessness.
The evidence base for testosterone and mood is, frankly, more grounded than the hypothesis SSRIs were designed around. A systematic review and meta-analysis published in JAMA Psychiatry found testosterone treatment was associated with meaningful reduction in depressive symptoms in men, with the strongest effects in middle-aged and hypogonadal populations. That’s not a fringe observation. It’s a measurable intervention producing measurable outcomes.
The man in that scenario needed a testosterone level. Not a symptom checklist.
What role does progesterone play in mood regulation?
Progesterone is a neurosteroid. When metabolized by the enzyme 5-alpha reductase, it converts to allopregnanolone, a compound that modulates GABA-A receptors in the central nervous system. GABA is the primary inhibitory neurotransmitter in the brain. It governs anxiety regulation, sleep architecture, emotional reactivity, and the baseline felt sense of calm.
This is the same receptor system that benzodiazepines act on. Progesterone achieves that modulation without the dependency risk, cognitive impairment, or withdrawal profile that come with chronic benzodiazepine use.
Progesterone deficiency is common. It begins declining in most women from their late 20s onward and accelerates in perimenopause. The clinical presentation frequently includes anxiety, insomnia, emotional dysregulation, OCD-like tendencies, and depressive symptoms. These women are regularly diagnosed with generalized anxiety disorder or major depressive disorder, then handed an SSRI or a benzodiazepine. The actual driver was a measurable, correctable hormonal deficiency.
Checking a progesterone level, asking about cycle regularity, understanding whether a patient has been on hormonal birth control for years: these are not alternative medicine questions. They’re foundational clinical questions that belong in any complete mood evaluation.
How does estradiol affect serotonin function?
Estradiol enhances and upregulates serotonin receptors. This is relevant because it produces a functionally similar effect to what SSRIs are designed to achieve, through a more physiological mechanism.
When estradiol drops, particularly in the transition into menopause, serotonergic function declines with it. The result is emotional blunting, flat affect, anhedonia, decreased libido. Estradiol also modulates dopamine in the prefrontal cortex and limbic system, which governs reward processing and motivation. The combined picture meets diagnostic criteria for major depressive disorder.
A menopausal woman presenting with these symptoms who has never had her estradiol measured hasn’t received a complete evaluation. Prescribing an SSRI without measuring estradiol in this population is treating downstream of the problem. The receptor function the SSRI is designed to support can often be addressed more directly by restoring the hormone that was regulating it.
Why should hormone evaluation come before psychiatric medication?
This is not an argument against psychiatric medication. Some patients need it. The question is when hormone levels get evaluated, and the answer should be: at the beginning, not after multiple medication trials have failed.
Hormones are objective. Measurable. You can track them over time and correlate them with symptoms. They give you the kind of data that symptom-based psychiatric screening, by its own design, cannot provide. There is no blood test for depression. But there is one for testosterone, estradiol, progesterone, and thyroid hormones. All of them have direct, documented mechanisms of action on mood. When providers check these first, they often identify the driver of the clinical presentation before reaching for a medication built on an unconfirmed theory.
That’s not unconventional thinking. It’s a complete evaluation.
The patient in front of you deserves that workup. And so do you, as the clinician trying to give them an honest answer.
Key takeaways
- Depression is a symptom with multiple possible upstream drivers, not a disease caused by confirmed serotonin deficiency.
- The Moncrieff 2022 umbrella review found no consistent evidence linking serotonin levels to depression across multiple study designs.
- Serotonin is a stress-adaptive signal. When chronically elevated or pharmacologically prolonged, it suppresses oxidative metabolism and shifts cellular function toward glycolysis. The metabolic side effects of long-term SSRI use are consistent with that shift.
- The six most widely prescribed SSRIs have been shown in vitro to disrupt steroidogenesis, decreasing androgens at concentrations close to therapeutic levels.
- Testosterone is dopaminergic and independently associated with clinical depression. Replacement in hypogonadal patients has meaningful evidence for mood improvement.
- Progesterone converts to allopregnanolone, a neurosteroid that modulates GABA-A receptors, producing calming and mood-stabilizing effects without the risk profile of benzodiazepines.
- Estradiol upregulates serotonin receptors. When estradiol drops, serotonergic function drops with it. This is measurable. It’s correctable.
Frequently asked questions
Is depression a disease or a symptom? Depression is a symptom. It is a downstream signal of underlying physiological disruption, not a condition with a single known cause, confirmable pathology, and predictable cure. This distinction changes how providers should approach evaluation and treatment.
What did the Moncrieff 2022 study find about serotonin and depression? Dr. Joanna Moncrieff’s umbrella review examined the full body of evidence supporting the serotonin hypothesis of depression. The review found no consistent evidence of a direct link between serotonin levels and depression. Some included studies showed elevated serotonin associated with depressive symptoms, which is the opposite of what the hypothesis predicts.
Can low testosterone cause depression? Yes. Low testosterone has been independently associated with clinical depression in multiple peer-reviewed studies and meta-analyses. Testosterone is dopaminergic and affects motivation, effort-reward processing, and cognitive function. Deficiency can present identically to major depressive disorder.
How does progesterone affect anxiety and depression? Progesterone is metabolized into allopregnanolone, a neurosteroid that modulates GABA-A receptors in the brain. GABA is the primary inhibitory neurotransmitter responsible for calm, sleep regulation, and emotional stability. Progesterone deficiency can present as anxiety, insomnia, OCD-like tendencies, and depression.
What is allopregnanolone? Allopregnanolone is a metabolite of progesterone. It acts on GABA-A receptors in the central nervous system, producing calming, anxiolytic, and mood-stabilizing effects. It acts on the same receptor system targeted by benzodiazepines, without the dependency and cognitive impairment that come with chronic use.
Does estradiol affect serotonin? Yes. Estradiol enhances and upregulates serotonin receptors. When estradiol drops, particularly in perimenopause and menopause, serotonergic function declines. This produces emotional blunting, anhedonia, and flat affect, symptoms commonly diagnosed as major depressive disorder.
Should providers check hormones before prescribing SSRIs? In many cases, yes. Hormones are measurable, objective data points with direct mechanisms of action on mood regulation. A complete evaluation that includes testosterone, progesterone, estradiol, and a full thyroid panel gives providers clinical information that symptom-based psychiatric screening alone can’t. This doesn’t replace psychiatric assessment. It precedes it.
What hormones should be checked in a patient presenting with depression? At minimum: total and free testosterone, progesterone (in cycling women, timed to the luteal phase), estradiol, and a full thyroid panel including TSH, Free T4, Free T3, and TPO antibodies. These cover the primary hormonal drivers of mood most commonly missed in standard workups.
Do SSRIs work at all? Some patients experience benefit from SSRIs. The point of this episode is not that SSRIs are useless. It’s that the mechanism they were designed to target has not been confirmed as the cause of depression. If a patient improves on an SSRI, the benefit may be arriving through a pathway other than serotonin correction. That matters because it means many patients aren’t getting to the root of the problem.
What is the monoamine hypothesis? The monoamine hypothesis is the theory that depression is caused by deficiencies in monoamine neurotransmitters, primarily serotonin. It’s been the dominant model for depression treatment since the late 1980s. Despite widespread adoption, it remains a hypothesis. The Moncrieff 2022 umbrella review is the most thorough examination of this theory to date, and it found the evidence insufficient.
Where can I learn more about hormones and mood regulation? The HRT University Master Course covers the physiology of testosterone, progesterone, estradiol, and thyroid in clinical practice. Module 2 (Male HRT) and Module 3 (Female HRT) address mood regulation mechanisms in depth. The course is jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC) and offers 30 CE credits.Can hormone replacement therapy replace psychiatric medication? That depends on the patient. For patients whose depressive symptoms are driven primarily by hormonal deficiency, HRT may resolve the presentation entirely. For others, a combination of hormonal correction and psychiatric support may be appropriate. The clinical decision should follow a complete evaluation, not a default to either approach.
